When I was diagnosed with Ulcerative colitis/Crohn’s disease six years ago, I was ignorant to the extent to which it would change my life. It altered all plans I had meticulously pieced together for a cohesive and creative existence within the world. The continual road of ups and downs not only affected me, they impacted my family, finances, and career. I knew people with UC/CD before I was diagnosed, yet had no idea of the daily struggles they faced, from immense pain and fatigue to brain fog to how your life stops when you have a flare. I lost my independence, financial nest egg, numerous jobs, relationships, and eventually myself.
#GivingTuesday is finally here, and Human Para has a great way to maximize your donation dollars to fund MAP research and make a difference in the lives of Crohn’s patients and people with MAP-driven diseases around the world. If you’re new to the #GivingTuesday movement, you may want to read our introductory post first.
On November 28th, starting at 8:00 a.m. EST, Facebook and the Bill & Melinda Gates Foundation will match funds donated to 501(c)(3) charities up to $50,000 per nonprofit, until the $2 million in matching funds run out. Facebook is also waiving the fees for all donations made on #GivingTuesday to nonprofits through their site.
We all know about Black Friday and Cyber Monday, but what is #GivingTuesday? In short – a great opportunity to fund some MAP research this holiday season!
Human Para’s #GivingTuesday campaign is hoping to raise $40,000 to fully fund our initial Joint Testing Study. All funds raised on #GivingTuesday will go directly to MAP research! If we raise the full amount needed for our initial study, we have more research projects waiting in the wings.
Human Paratuberculosis Foundation seeks to sponsor innovative research projects which will add to our understanding of MAP’s role in human disease. We encourage cooperative efforts among investigators, research centers, and other resources.
Human Para is pleased to announce our first research project in conjunction with 10 investigators from 5 different countries. This initial study seeks to confirm that Crohn’s disease patients have a significantly higher rate of MAP infection than individuals that do not have Crohn’s, and to compare more recent rapid culture methods from multiple laboratories. Our funding goal is $40,000 which will allow 210 samples (60 from Crohn’s patients, 150 controls) to be tested. MAP cultures and antibody studies will be performed in the laboratories of John Aitken, Timothy Bull, Irene Grant, Horacio Bach, Peilin Zhang and Raghava Potula.
by Judith Eve Lipton, MD
originally published June 7, 2015, revised October 24, 2017
I receive many letters from people around the world asking about treating Crohn’s disease with antibiotics, under the theory that Crohn’s disease is an infection caused by MAP, Mycobacterium avium subspecies paratuberculosis. I am a psychiatrist, not a gastroenterologist (GI), and not qualified to make specific suggestions about treating Crohn’s disease. I never treat any GI patients myself, and never did. I will never tell people specific doses or protocols for treating MAP because every patient is different. If you elect to learn more and follow this path, you will need your own local physician. I am only offering general information.
Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other MAP-driven diseases.
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date MAP information to assist healthcare professionals and patients around the world to make informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Human Para is pleased to share the consensus article from the 2017 MAP conference in Philadelphia. This effort represents a historic collaboration of the world’s experts on Mycobacterium avium spp. paratuberculosis (MAP), who are concerned about the impact of MAP on human health. The goal of this collaboration is to advance better treatment options for patients suffering from MAP-driven conditions.
Upcoming Events November 28, 2017 We all know about Black Friday and Cyber Monday, but what is #GivingTuesday? In short – a great opportunity to fund some MAP research this holiday season! Human Para's #GivingTuesday campaign is hoping to raise $40,000 to...
Human Paratuberculosis Foundation has created an information pack designed with patients in mind. This downloadable pack, containing links to the latest research and resources on MAP science, can be printed or sent in electronic format. Presented in a brief, easy to read format, it provides an introduction to MAP in Crohn’s and other diseases, discusses detection rates, and sets out therapeutic options including clinical trials. A full page of additional resources follows, concluding with a short synopsis about the Human Para organization. This can be used to help you prepare to get the most out of your next visit with your healthcare professional. Understanding your condition and the latest research can increase your chances of improving and maintaining your health.
Human Paratuberculosis Foundation is pleased to announce that it is seeking research proposals from qualified applicants that will advance our knowledge about the role that Mycobacterium avium spp. paratuberculosis (MAP) plays in human disease. MAP has been detected in significantly higher numbers in patients with Crohn’s disease, Type 1 Diabetes, Multiple Sclerosis, Sarcoidosis, Hashimoto’s Thyroiditis and Psoriasis, and emerging research indicates that MAP may be involved in other conditions such as Parkinson’s disease, Blau Syndrome, Rheumatoid Arthritis and Lupus. It has been shown that patients with these conditions have genetic vulnerabilities which may hinder the immune system’s ability to correctly recognize pathogens, predisposing them to bacteria such as MAP.
Human Para now seeks to sponsor innovative research projects which will add to our understanding of MAP’s role in human disease. For further details and instructions on how to submit a proposal, please see the Application Instructions.